Eli Lilly, WuXi PharmaTech deal

The companies partnered to develop and commercialize an undisclosed small molecule in China to reduce cardiovascular events in patients with dyslipidemia. WuXi plans to lead registration, development and manufacturing in China, which would allow the candidate to benefit from China FDA’s accelerated regulatory pathway for domestic drugs. ...